Does New York Medicaid Cover Wegovy or Zepbound?
New York (NY) GLP-1 access depends on three state-specific policy questions before it ever gets to pricing: does New York Medicaid cover weight-loss GLP-1s, has New York expanded Medicaid under the ACA, and does the state employee health plan cover them. Answering those first tells you whether you're likely working with insurance or planning for cash-pay.
New York Medicaid GLP-1 coverage: what the state's own documents say
NYRx, which covers fee-for-service and mainstream managed care members, excludes GLP-1s for weight loss and covers Wegovy only with a cardiovascular disease diagnosis plus BMI of 40 or higher, and Zepbound only with an obstructive sleep apnea diagnosis plus BMI of 40 or higher (each also needs lifestyle-modification participation and has a lifetime limit of two treatment attempts).
Checked September 20, 2026 against: newyork.fhsc.com, newyork.fhsc.com, law.cornell.edu, health.ny.gov.
New York state employee health plan: what the plan's own documents say
New York's Empire Plan prescription program lists Wegovy (injection and oral tablets), Zepbound, Foundayo, Saxenda, Contrave, Qsymia, liraglutide (weight management) and orlistat as covered anti-obesity agents on its July 2026 formulary, each requiring prior authorization; the prior-authorization criteria (BMI, lifestyle) could not be retrieved. This describes the Empire Plan prescription program; HMO enrollees and members whose drug coverage comes through a union Employee Benefit Fund are covered under different formularies.
Checked September 20, 2026 against: cs.ny.gov, cs.ny.gov, cs.ny.gov.
Notable insurers active in New York (not independently verified): EmblemHealth, Anthem Empire BCBS, UnitedHealthcare.
Why GLP-1 coverage varies this much by state
Medicaid is a state-federal partnership, not a single national program. Each state Medicaid agency sets its own preferred drug list (PDL) and prior-authorization criteria within federal minimum requirements. Weight-loss drugs are not a federally mandated Medicaid benefit, so states choose independently whether to cover them - which is why only 10 of 50 states currently do (New York is not one of them).
State employee health plans are a useful bellwether. These plans cover hundreds of thousands of state workers and negotiate directly with pharmacy benefit managers, so their coverage decisions often signal where commercial insurers in that state are heading. North Carolina's State Health Plan, for example, ended coverage of weight-loss GLP-1s on April 1, 2024, after its board voted 4-3 to cut it citing the drugs' high cost - a case that other states and large employers have watched closely.
Medicaid expansion status shapes who even has coverage to begin with. States that haven't adopted ACA Medicaid expansion have narrower Medicaid eligibility overall, which - combined with the weight-loss GLP-1 exclusion most states apply regardless of expansion status - pushes a larger share of residents in those states toward commercial insurance, telehealth, or manufacturer self-pay as their only realistic path.
National reference pricing (same nationwide - your actual cost depends on your plan)
These prices are the same across all 50 states because manufacturer list prices, self-pay programs, and telehealth pricing don't vary by state - only insurance coverage and copay do, which is why the New York-specific policy facts above matter more than the table below for predicting your actual cost.
| Drug | Covered by insurance | Manufacturer self-pay | Telehealth | Cash retail |
|---|---|---|---|---|
| Wegovy 14.9% weight loss | $63 | $349 | $329 | $1,349 |
| Ozempic 11.6% weight loss | $63 | - | $399 | $1,028 |
| Wegovy (oral 25mg) 13.6% weight loss | $63 | $149 | $449 | $1,349 |
| Zepbound 22.5% weight loss | $88 | $299 | $499 | $1,059 |
| Mounjaro 20.9% weight loss | $88 | - | $499 | $1,069 |
| Saxenda 8.4% weight loss | $63 | - | $399 | $1,349 |
| Foundayo (orforglipron) 14.7% weight loss | $63 | $149 | - | $1,099 |
| CagriSema 20.4% weight loss | $88 | $599 | - | $1,499 |
Cheapest cash-pay GLP-1 paths for New York residents
Manufacturer direct prices (LillyDirect, NovoCare) are usually cheapest. Updated May 2026.
| Drug | Insurance | Mfr direct | Telehealth (brand) | Telehealth (compd) | Cash retail | Get it |
|---|---|---|---|---|---|---|
| Wegovy 14.9% weight loss | $63 | $349 | $329 | $249 cheapest | $1,349 | Get →ad |
| Ozempic 11.6% weight loss | $63 | - | $399 | $199 cheapest | $1,028 | Get →ad |
| Wegovy (oral 25mg) 13.6% weight loss | $63 | $149 cheapest | $449 | - | $1,349 | Get →ad |
| Zepbound 22.5% weight loss | $88 | $299 cheapest | $499 | $299 cheapest | $1,059 | Get →ad |
| Mounjaro 20.9% weight loss | $88 | - | $499 | $299 cheapest | $1,069 | Get →ad |
| Saxenda 8.4% weight loss | $63 | - | $399 cheapest | - | $1,349 | Get →ad |
| Foundayo (orforglipron) 14.7% weight loss | $63 | $149 cheapest | - | - | $1,099 | Get →ad |
New York carrier coverage details
National carriers active in New York (this list is not independently verified). Drill into each carrier's prior-auth requirements, formulary, and appeal playbook.
Frequently asked questions
Does New York Medicaid cover Wegovy or Zepbound for weight loss?
No. NYRx, which covers fee-for-service and mainstream managed care members, excludes GLP-1s for weight loss and covers Wegovy only with a cardiovascular disease diagnosis plus BMI of 40 or higher, and Zepbound only with an obstructive sleep apnea diagnosis plus BMI of 40 or higher (each also needs lifestyle-modification participation and has a lifetime limit of two treatment attempts). This was checked against New York's own documents on September 20, 2026; coverage rules change often, so confirm with your plan before relying on it. Coverage for type 2 diabetes (Ozempic, Mounjaro) is a separate question. Medicare's GLP-1 Bridge, which started July 1, 2026, works separately from Medicaid and applies in every state.
Has New York expanded Medicaid under the ACA?
Yes - New York has adopted Medicaid expansion, which broadens who qualifies for Medicaid coverage generally, though it does not by itself guarantee GLP-1 weight-loss coverage (see above).
Does the New York state employee health plan cover Wegovy or Zepbound?
Yes. New York's Empire Plan prescription program lists Wegovy (injection and oral tablets), Zepbound, Foundayo, Saxenda, Contrave, Qsymia, liraglutide (weight management) and orlistat as covered anti-obesity agents on its July 2026 formulary, each requiring prior authorization; the prior-authorization criteria (BMI, lifestyle) could not be retrieved. This describes the Empire Plan prescription program; HMO enrollees and members whose drug coverage comes through a union Employee Benefit Fund are covered under different formularies. This was checked against New York's own plan documents on September 20, 2026; plan terms are reset each plan year, so confirm with your plan before relying on it.